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Abstract 
Background 
An involvement of selective serotonin reuptake inhibitors (SSRIs) in increasing 
the risk of malformations, neonatal withdrawal syndrome, has been suggested 
recently. Here, we aimed to investigate the contribution of individual 
pharmacogenetics of SSRI on infants’ outcome. We also estimated the 
umbilical/maternal plasma SSRI concentration ratio in the pregnant women still 
on SSRI therapy at the time of delivery. 
Methods 
Thirty-four pregnant women, referred to our hospital from January 2011 to July 
2015, who were given SSRIs in the third trimester, and related children, were 
considered. The umbilical/maternal plasma SSRI concentration ratio was 
estimated in 15 mothers still on SSRI therapy at the time of delivery. For 
patients with pharmacokinetic analysis, blood samples were collected for 
pharmacogenetic analyses. 
Results 
Nineteen newborns presented clinical signs possibly related to drug toxicity. A 
high umbilical/maternal plasma ratio of SSRI was observed in 10 out of the 15 
evaluated newborns. Five mothers were intermediate metabolizers and one poor 
metabolizer for the major CYP enzyme involved in pharmacokinetic pathway.  
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Conclusions 
Individualized psychopharmacologic treatment that takes into account mother’s 
exposure to SSRI concentrations and eventually their genetic background may 
become the standard of care to maximize drug benefit and minimize risks to the 
newborn. 
 
Key words:  pharmacokinetics, pharmacogenetics, SSRIs, pregnancy 
 
 
Introduction 
Depression is a disorder affecting 7%-15% women in general population [1], 
12.7%-18.4% of pregnant women [2] and is a leading cause of disability [3]. 
Women with severe, chronic, or recurrent syndromes require pharmacotherapy. 
Selective serotonin reuptake inhibitors (SSRIs) are commonly used 
antidepressants that act by inhibiting serotonin reuptake in the synaptic cleft. 
Medications in this group include paroxetine, sertraline, citalopram, 
escitalopram, and venlafaxine (combined serotonin-norepinephrine reuptake 
inhibitors). In the past years, SSRIs have been largely prescribed to pregnant 
women suffering from psychiatric problems, in particular from depression and 
anxiety. This is based on the assumption that the potential negative effects of 
untreated psychiatric symptoms from pregnant women largely outweigh the 
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limited risk for the fetus, especially if the SSRIs are given to women late in the 
course of the pregnancy [4-6]. 
Data about infants exposed in uterus to SSRIs are limited due to difficulty in 
determining exactly when exposure had occurred during pregnancy, the severity 
of the maternal psychiatric disorder, compliance to therapy, gestational age at 
exposure, antidepressant dose, comorbidity, and delivery complications. 
Possible complications following antenatal exposure to antidepressants include 
adverse pregnancy outcome spontaneous abortion, stillbirth, prematurity, 
intrauterine growth restriction, neonatal mortality, and, with paroxetine, also 
teratogenicity [7-9]. 
Moreover, SSRI intake during pregnancy has also been associated with an 
increased risk for other neonatal complications such as low birth weight, 
admission to special care nurseries, persistent pulmonary hypertension [10], and 
poor neonatal adjustment syndrome (PNAS) [11]. The latter may present as 
respiratory distress, hypoglycemia, agitation, tremors, irritability, restlessness, 
jitteriness, low Apgar scores, altered muscle tone, feeding difficulties, and 
seizures [12]. Among SSRIs, paroxetine and to a significantly lower extent 
fluoxetine are associated with a slight increase in the risk of fetal malformations, 
namely cardiovascular ones [2]. Reported incidence of PNAS accounts for up to 
30% of newborns exposed to SSRIs and SNRIs [13] from 5% to 85% [14]. 
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Symptoms are generally mild, self-limited, and resolve within a couple of 
weeks with the notable exception of few cases persisting for months [12-14]. 
Despite this increased risk of neonatal maladaptation, it seems that SSRI can 
play a protective role on some deleterious reproductive outcomes, maybe 
reducing maternal depressive symptoms [15] 
In the general population, SSRIs are perceived as wide therapeutic index drug, 
and therapeutic drug monitoring (TDM) is not routinely performed in the 
clinical practice. However, according to the recently published AGNP consensus 
guidelines [16], significant correlations between plasma concentrations of SSRIs 
and clinical outcome (both efficacy and safety outcomes) have been reported, 
with most of the molecules having a score level of recommendation of 1 or 2 for 
the use of TDM. Thus, pregnant women having high SSRI plasma 
concentrations might be at risk to experience drug-related complications for 
themselves, and/or to overexpose their fetus to these drugs, increasing also their 
risk to experience poor perinatal outcome. 
Expression of CYP genes, involved in SSRIs hepatic first-pass metabolism, is 
influenced by a combination of factors including genetic polymorphisms. 
Distinct CYP pharmacogenetic phenotypes, derived from functional genetic 
variants, have been associated with the dose requirement, drug efficacy, and 
occurrence of severe toxicities [17]. Pharmacogenetic guidelines have been 
published to provide information regarding the interpretation of CYP2C19 
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and/or CYP2D6 genotype test, to guide SSRI dosing [18]. In the case of 
CYP2C19, two loss-of-function alleles (*2, *3) create a premature stop codon, 
whereas *17 results in enhanced gene transcription and an increased metabolic 
activity [18,19]. For CYP2D6, the major impaired variant alleles are as follows: 
*3–*6 (non-functional), while CYP2D6 gene duplications and a promoter 
polymorphism explain a fraction of increased metabolism [19]. 
The present study aimed at exploring drug-related perinatal complications in 
newborns from mothers given SSRI during pregnancy and their correlations 
with estimated umbilical/maternal plasma SSRI concentration ratio, in the 
pregnant women still on SSRI therapy at the time of delivery, and 
polymorphisms in genes involved in SSRI metabolism. 
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Materials and methods 
Patients 
Pregnant patients were recruited between January 2011 and July 2015 from the 
antenatal clinic of the Luigi Sacco University Hospital (Milano, Italy). Inclusion 
criteria were as follows: pregnant women treated with SSRI during the third 
trimester, physiologic pregnancy, no other pharmacologic treatment, and single 
pregnancy. All patients provided their written informed consent prior to any 
study procedure. The study was approved by the local ethics committee (Luigi 
Sacco University Hospital). 
 
Pharmacokinetic analyses 
Blood samples for the measurement of plasma drug concentrations in the 
mothers and newborns were collected at delivery.  For the newborns, the blood 
samples were collected from the umbilical cord. After drawing, the collected 
blood samples were handled on ice; plasma was separated by centrifugation and 
stored at −20 °C until analysis at the centralized pharmacokinetics laboratory of 
the pharmacology unit. Plasma concentrations of paroxetine, venlafaxine, 
sertraline, citalopram, and escitalopram were quantified using liquid 
chromatography/tandem mass spectrometry methods developed and validated 
in our laboratory [20]. The lower limit of quantification (LLOQ) of the method 
was 5 ng/mL for all analytes. The performance of these methods was tested 
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during each analytical run using internal quality controls, and blinded samples 
were sent monthly as part of the LCG Standard Proficiency Testing Schemes 
for Psychoactive Drugs (http://www.lgcpt.com/default.aspx). 
Besides absolute plasma concentrations, the umbilical cord/maternal plasma 
ratio was also estimated for each drug. According to the AGNP guidelines [16], 
we considered the following ranges of drug concentrations as therapeutic 
windows: paroxetine, 30-120 ng/mL; venlafaxine (plus the active metabolite), 
100-400 ng/mL; sertraline, 10-150 ng/mL; and citalopram, 50-100 ng/mL. 
 
Genotyping 
Peripheral blood samples were collected from pregnant women who underwent 
pharmacokinetic analysis. Maternal DNA was isolated using an automatic DNA 
extraction system (Maxwell® 16 System, Promega, Madison, WI, USA) 
according to the manufacturer’s instructions. Polymorphisms were determined 
by Real-Time PCR using LightSNiP® (TIB-MolBiol, Berlin) or TaqMan® 
assay (Thermo Fisher Scientific, Waltham, MA, USA) according the 
manufacturer’s instructions. We evaluated the functional variant mapping in 
CYP2D6 (*3,*4,*5,*6, rs1080985 promoter variant, gene duplication) for 
paroxetine, venlafaxine, and citalopram and in CYP2C19 (*2, *3, *17) for 
sertraline. 
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Assessment of newborns’ outcome 
Newborns exposed to SSRIs/SNRIs in utero had their vitals assessed at birth and 
every 4 hours for the first 24 hours including the use of pulse oximetry at each 
assessment as suggested by the Canadian Guidelines [21]. The first SpO2 was 
taken at birth if Apgar score was low, otherwise at approximately 1 hour post 
delivery. Newborns with a low SpO2 or with respiratory distress were treated 
with O2 supplementation. The diagnosis of PNAS was made after other possible 
causes of the newborn’s symptoms have been ruled out [22]. Symptoms of 
PNAS (low Apgar score, restlessness, agitation, irritability, lethargy, poor 
feeding, hypoglycemia, hypothermia, respiratory distress, altered muscle tone, 
hyperreflexia, jitteriness) were annotated on newborn’s medical record until they 
were resolved. All children were hospitalized for at least 72 hours. Respiratory 
distress was treated with ventilatory support and/or oxygen supplementation, 
hypoglycemia with intravenous/oral glucose, and minor symptoms were treated 
providing supportive care such as a quiet, low-light environment. 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
- 11 - 
 
Results 
Patient characteristics and clinical outcome 
During the study period, 34 women with reported third trimester exposure to 
SSRIs and their newborns were included as follows: 11 were treated with 
paroxetine, 4 with venlafaxine, 15 with sertraline, and 4 with citalopram. Table 
1 details the characteristics of the study population and the psychiatric diagnosis 
of the women at admission. 
All mothers were Caucasian and carried a singleton pregnancy. Patients had a 
medium-low socio-economic status as follows: 20% with a University degree, 
25% with a high school diploma, and 55% with a primary school diploma. 
Approximately 60% of women were married, 40% were living with their own 
partner and/or family of origin. 
Three mothers and three children had some missing data (nd). Pregnant women 
were at mean age of 36 years (median 35 years). Of about 18 (53%) had a 
vaginal delivery and 16 (47%) delivered by cesarean section (CS). More in 
detail, CS was carried out for previous CS (3), maternal choice, (4), suspected 
placental abruption (2), premature rupture of membranes (2), labor dystocia (1), 
and fetal distress (5). 
We evaluated 34 newborns as follows: 17 males (50%) and 17 females (50%). 
Median gestational age, weight, length, and head circumference were 39 weeks, 
3260 grams, 49.5 cm and 34 cm, respectively. These characteristics are in line 
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with those of the general newborn population [23]. Two newborns were late 
preterm and four small for gestational age. Nineteen (56%) newborns showed 
signs or symptoms consistent with PNAS. The most represented symptoms 
(47%) were the neurological ones including tremors, irritability, hyper-
hypotonus, hyperreflexia, jitteriness, and restlessness. Seven newborns had a 
one-minute low Apgar score (≤7). Respiratory distress requiring oxygen 
supplementation was present in five newborns, and none manifested pulmonary 
hypertension or seizures. Seven newborns required admission in the neonatal 
ward. 
 
Pharmacokinetics analysis 
Fifteen out of the 34 pregnant women were still on SSRI therapy at the time of 
delivery, whereas the remaining stopped the drug a few days before partum. 
Overall, plasma drug concentrations above the LLOQ were detected in all the 15 
mothers and 10 newborns (Table 2). 
None of the pregnant women treated with citalopram reached therapeutic drug 
concentrations according to AGNP guidelines (Table 2) [16]. Despite the 
subtherapeutic citalopram concentrations measured in the pregnant women, the 
newborns had quantifiable drug concentrations, resulting in higher 
umbilical/plasma ratios compared with those measured with other SSRIs. 
Worthy of mention, in one out of the three newborns, the concentrations of 
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citalopram were higher compared with those measured in the mother, resulting 
in an umbilical/plasma ratio of 141.6%. No trend for association between 
citalopram pharmacokinetics and newborns’ outcome was observed. 
Subtherapeutic exposure was also observed in the two pregnant women given 
paroxetine (Table 2). Conversely, the only pregnant woman given venlafaxine 
had drug plasma concentrations in the therapeutic range. Interestingly, in the 
corresponding newborn, we measured a venlafaxine concentration of 78.9 
ng/mL, a value close to 100 ng/mL, considered as the minimum therapeutic 
concentration in adults. In this case, we also observed an umbilical/plasma ratio 
of 39.5%. 
As shown in Table 2, 50% of the pregnant women given sertraline had 
therapeutic drug concentrations at the time of delivery, with umbilical/plasma 
ratios ranging from 23.9% to 102.4%.  
 
Pharmacogenetic analysis 
Overall, variant alleles in CYP2C19 and CYP2D6 genes were detected in 8 out 
of 15 mothers. 
More in detail, CYP2C19 gain- and loss-of-function alleles were found in four 
mothers and CYP2D6 loss-of-function alleles in two mothers (Table 2). 
Paroxetine is extensively metabolized by CYP2D6 to compounds with little 
pharmacological activity toward serotonin reuptake inhibition. Variations in 
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CYP2D6 activity may result in lower or greater exposure to these drugs. For an 
individual with CYP2D6 reduced activity, the guideline recommended an 
alternative drug not predominantly metabolized by CYP2D6 or, if a paroxetine 
use is warranted, a 50% dose reduction. Interestingly, a mother ID1 with a 
CYP2D6 deletion in heterozygous (*5) showed higher paroxetine levels, and her 
child presented a more severe adverse outcome (Table 2). 
The major metabolic pathway for sertraline is CYP2C19, and the enzyme 
activity variation may result in altered drug exposure. Interestingly, a newborn 
ID25 presented severe adverse events, and her mother carried two loss-of-
function alleles of CYP2C19 (*2/*2) (Table 2). 
Citalopram and its N-demethylated metabolites exist as racemic compounds. In 
vitro and in vivo tests showed that the effects of citalopram and N-
demethylcitalopram are mainly or solely due to the S-enantiomers. The 
formation of R/S-demethylcitalopram is catalyzed mainly by the isoenzymes 
CYP2C19. Defective maternal alleles were detected in ID24 (Table 2). 
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Discussion 
The use of SSRI during pregnancy has been increasing, currently occurring in 
up to 2%-6% of pregnant women [6]. Mothers taking SSRI are more likely to 
be older, having undergone cesarean section more frequently than the general 
population. Intrauterine exposure may lead to neonatal symptoms especially 
from the central nervous system; PNAS is the most frequently reported one. 
How an exposure to SSRIs leads to PNAS is still unknown. PNAS could be the 
consequence of abstinence due to the discontinued distribution of the 
pharmacological substance at delivery as well as to serotonergic 
overstimulation or genetic predisposition. 
A lot has been, indeed, written on the use of SSRI during pregnancy and 
possible short- and long-term negative outcomes on neonates [3-10]. We know 
that different degrees of outcomes are possible, and not all the newborns 
exposed to SSRIs during pregnancy definitely will develop a negative outcome. 
For this reason it is not possible to casually establish whether the adverse 
outcome of infants in utero exposed to SSRIs is worse than in a general 
population. However, a recent study has shown that the profile of 
neurobehavioral development was different for SSRI-exposed versus non-
exposed infants [24]. So far, still little is known about the possible etiologic 
mechanism that could not only explain the adverse neonatal effects but also the 
degree of clinical involvement and presentation in the early period after birth. 
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On this regard, pharmacokinetics and pharmacogenetics might potentially 
explain a part of the observed variability in the clinical neonatal outcome after 
in utero exposure to SSRIs (reviewed in [25]). 
Fifty-six percent of newborns in our study presented one or more symptoms 
consistent with PNAS. Seven out of 34 infants required admission to the 
neonatal ward mainly for respiratory distress syndrome or neurologic disorders. 
Interestingly, for each drug, the worst adverse outcome was observed in infants 
born to the mothers with the high umbilical/maternal plasma ratio of SSRI and 
altered CYP activity as emerging from the pharmacogenetic analysis. More in 
detail, case ID1, whose mother had a CYP2D6 gene deletion (*5), presented a 
low one-minute Apgar score, respiratory distress, bradycardia, hypotonia, and 
hyporeflexia and needed resuscitation efforts and ventilatory support during the 
first 18 hours of life; the patient also showed hypoglycemia and episodic phasic 
contraction of all limb miming seizures, EEG and cerebral ultrasound were 
normal. Postural muscle response onset latencies were significantly shorter than 
the responses found in age-matched normal children, later she presented the 
reduction of isolated arm and leg movements, increased unilateral tendon reflex. 
These symptoms resolved in two months. Interestingly, this case showed the 
highest maternal plasma paroxetine concentration. Taken together, the PK/PG 
characteristics allowed us to speculate that the observed adverse outcome may 
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be reasonably explained by a decreased metabolism of the paroxetine into the 
mother. 
Another interesting case, ID25, presented a mild respiratory distress at birth, 
self-limited by 3 hours, accompanied by jitteriness and tremors that lasted 48 
hours. Generalized hypotonia resolved at one month of life. Interestingly, her 
mother carries two loss-of-function alleles of CYP2C19 (*2/*2), which are 
consistent with a poor metabolizers phenotype, and therefore reduced clearance 
of sertraline. This is indirectly supported also by a high sertraline 
umbilical/maternal plasma ratio. 
A very interesting case, at least from a pharmacokinetic viewpoint, is mother 
ID16, being characterized by the highest plasma drug concentrations, highest 
exposure measured in the plasma newborn, with concentrations that approximate 
those considered as therapeutic in adults [16] and poor neonatal outcome 
(prematurity, low Apgar Score needing neonatal resuscitation). 
Even if PNAS is self-limiting and transient, newborns of SSRI treated mother 
should be monitored in the first few days of life. Management of PNAS 
primarily consists of supportive care. Identification of infants at risk of PNAS—
because of the severity of maternal psychiatric illness, maternal age, cesarean 
section, prematurity, or low birth weight—is critical to child management since 
it could significantly influence the neonatal outcomes. 
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Several limitations do exist in our preliminary observations, such as the presence 
of potential confounders, as the difficulty to determine exactly when the 
exposure to SSRIs occurred. Moreover, a significant percentage of mothers 
withdrew SSRIs a few days before delivery, a condition that did preclude a 
complete analysis of potential correlations between clinical outcome, TDM, and 
pharmacogenetic results. Furthermore, with regard to the pharmacogenetic 
aspect, we only took into account the maternal genetic background and the 
major genetic variants that affect the expression and activity of the CYP 
enzymes. Finally, the possibility that other non-genetic, non-pharmacokinetic 
factors may have affected the outcome of the studied newborns cannot be 
definitively ruled out. 
 
Conclusions 
Our preliminary observation suggests that genetic polymorphisms that affect 
SSRI metabolism may play a role, together with other clinical covariates, in the 
development of PNAS. Despite the observational design, we are confident that 
our hypothesis/generating investigation may provide the rationale for the design 
of a large, adequately powered, prospective study aimed at formally 
investigating the contribution of pharmacokinetics/pharmacogenetics on the 
outcome of pregnant women given SSRIs. 
 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
- 19 - 
 
References 
1. Farr SL, Dietz PM, O’Hara MW, et al. Postpartum anxiety and comorbid 
depression in a population-based sample of women. J Womens Health 
(Larchmt). 2014;23:120-128. 
2. Tran H, Robb AS. SSRI use during pregnancy. Semin Perinatol. 
2015;39:545-547. 
3. Committee on Obstetric Practice. Screening for Neonatal Depression. 
American College of Obstetrician and Gynecologist. Number 630, May 
2015. 
4. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in 
pregnancy. Am J Obstet Gynecol. 2007;196:544.e1-544.e5. 
5. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications 
during pregnancy: a multisite study. Am J Obstet Gynecol. 
2008;198:194.e1-5. 
6. Bakker MK, Kölling P, van den Berg PB, et al. Increase in use of selective 
serotonin reuptake inhibitors in pregnancy during the last decade, a 
population-based cohort study from the Netherlands. Br J Clin Pharmacol. 
2008;65:600-606. 
7. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-
reuptake inhibitors during early pregnancy and risk of congenital 
malformations: updated analysis. Clin Epidemiol. 2010;2:29-36. 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
E
- 20 - 
 
8. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in 
pregnancy. CNS Drugs. 2009;23:493-509. 
9. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy 
and the risk of preterm delivery and fetal growth restriction. J Clin 
Psychopharmacol. 2009;29:555-560. 
10. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to 
antidepressants and persistent pulmonary hypertension of the newborn: 
systematic review and meta-analysis. BMJ. 2014;348:f6932. 
11. Kieviet N, Hoppenbrouwers C, Dolman KM, et al. Risk factors for poor 
neonatal adaptation after exposure to antidepressants in utero. Acta 
Paediatr. 2015;104:384-931. 
12. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. The effect of 
prenatal antidepressant exposure on neonatal adaptation: a systematic 
review and meta-analysis. J Clin Psychiatry. 2013;74:e309-e320. 
13. Pearlstein T. Depression during Pregnancy. Best Pract Res Clin Obstet 
Gynaecol. 2015;29:754-764. 
14. Salisbury AL, O'Grady KE, Battle CL, et al. The roles of maternal 
depression, serotonin reuptake inhibitor treatment, and concomitant 
benzodiazepine use on infant neurobehavioral functioning over the first 
postnatal month. Am J Psychiatry. 2016;173:147-157. 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
- 21 - 
 
15. Malm H, Sourander A, Gissler M, et al. Pregnancy complications following 
prenatal exposure to SSRIs or maternal psychiatric disorders: results from 
population-based national register data. Am J Psychiatry. 2015;172:1224-
1232. 
16. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines 
for therapeutic drug monitoring in psychiatry: update 2011. 
Pharmacopsychiatry. 2011;44:195-235.  
17. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic 
variation. Pharmacol Ther. 2013;138:103-141. 
18. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics 
Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 
genotypes and dosing of selective serotonin reuptake inhibitors. Clin 
Pharmacol Ther. 2015;98:127-134. 
19. Llerena A, Dorado P, Ramírez R, et al. CYP2D6 -1584C>G promoter 
polymorphism and debrisoquine ultrarapid hydroxylation in healthy 
volunteers. Pharmacogenomics. 2013;14:1973-1977. 
20. Baldelli S, Fucile S, Cattaneo D, et al. Development of a LC-MS/MS 
method for therapeutic drug monitoring of antidepressants and 
antipsychotics in human plasma. Ther Drug Monit. 2011;33:528. 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
- 22 - 
 
21. Perinatal services BC antidepressant use during pregnancy: considerations 
for the newborn exposed to SSRIs/SNRIs. Available at: 
http://www.perinatalservicesbc.ca/Documents/Guidelines-
Standards/Newborn/AntidepressantUseExposedNewbornGuideline.pdf. Last 
accessed November 21, 2016. 
22. Forsberg L, Navér L, Gustafsson LL, et al. Neonatal adaptation in infants 
prenatally exposed to antidepressants—clinical monitoring using Neonatal 
Abstinence Score. PLoS One. 2014;9:e111327. 
23. Grummer-Strawn LM, Reinold C, Krebs NF. Use of World Health 
Organization and CDC Growth Chart for children aged 0-59 months in the 
United States. Available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5909a1.htm. Last 
accessed March 25, 2016. 
24. Salisbury AL, O'Grady KE, Battle CL, et al. The Roles of Maternal 
Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant 
Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First 
Postnatal Month. Am J Psychiatry. 2016;173:147-57. 
25. Giudici V, Pogliani L, Cattaneo D, et al. Serotonin reuptake inhibitors in 
pregnancy: can genes help us in predicting neonatal adverse outcome? 
Biomed Res Int. 2014;2014:276918. 
 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Table 1. Characteristics of study population 
 
Pregnant 
women (n = 34) 
Age (years) 34.6±4.5 
BMI before pregnancy (kg/m2) 24.2±4.6 
BMI at delivery (kg/m2) 29.1±4.9 
Smoking (any quantity) 13 (38%) 
Primiparity 11 (32%) 
Major Depressive Disorder 12 (35%) 
Anxiety Disorder (mainly Panic Disorder) 6 (18%) 
Mixed Anxiety-Depressive Disorder 15 (44%) 
Other diagnosis 1 (3%) 
Data are presented as mean ± standard deviation or absolute number (%) 
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Table 2. Individual pharmacokinetic, pharmacogenetic data and infant’s adverse outcome 
SSRI Patient ID 
Drug dose 
(mg/day) 
Mother’s 
[drug] 
(ng/mL) 
Infant’s 
[drug] 
(ng/mL) 
Umbilical/
Maternal 
ratio (%) 
Major CYP 
metabolizers  
Mother’s 
genotypes 
*Expected 
phenotype* 
#Infant’s adverse outcome 
immediately after delivery 
(later events in brackets) 
1 20 48.6 10.3 21.2 *1/*5 IM Prematurity, low Apgar score, RDS, neurologic symptoms 
Paroxetine 
32 25 23.4 9.1 38.9 
CYP2D6 
*1/*4 IM None (acrocyanosis at 8 hours of life) 
          
Venlafaxine 16 150 199.8 78.9 39.5 CYP2D6 *1/*1 EM Prematurity, low Apgar score 
          
27 75 89.0 35.5 39.9 *1/*1 EM None (tremors at 24 hours of life) 
22 100 32.7 7.8 23.9 *2/*17 IM None (poor feeding) 
30 75 25.3 <5  *1/*1 EM SGA 
25 50 24.5 11.1 45.3 *2/*2 PM RDS, neurologic symptoms 
14 75 12.7 13.0 102.4 *2/*17 IM None 
15 25 9.5 <5  *1/*1 EM None 
28 75 9.4 <5  *1/*17 UM SGA 
29 75 9.4 <5  *1/*17 UM None 
23 50 9.2 6.5 70.7 *1/*1 EM SGA 
Sertraline 
10 50 7.4 <5  
CYP2C19 
*1/*1 EM Low Apgar score 
          
11 5 10.1 14.3 141.6 *1/*1 EM None Citalopram 
24 10 9.3 5.5 54.3 
CYP2C19 
*1/*2 IM Neurologic symptoms 
Patients are listed in order of decreasing values of mother’s concentration for each drug. 
*Expected genotype defined according pharmgkb guideline (www.pharmgkb.org): Extensive Metabolizer (EM), Intermediate Metabolizer (IM), Poor Metabolizer (PM). 
#SGA: small gestational age; RDS: respiratory distress syndrome 
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